OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Reichert on Investigating Novel Agents and Pathways in Prostate Cancer

August 23rd 2023

Zachery Roger Reichert, MD, PhD, discusses the effects novel agents and pathways have had on the treatment of patients with prostate cancer.

Dr Hammers on Ongoing Investigations in Advanced RCC

August 23rd 2023

Hans Hammers, MD, PhD, discusses ongoing and planned investigations with the use of HIF2α inhibitors and triplet therapies in patients with advanced renal cell carcinoma.

Dr Hamilton on the Use of ADCs in Breast Cancer

August 23rd 2023

Erika P. Hamilton, MD, discusses the use and sequencing of antibody-drug conjugates in patients with hormone receptor-positive/HER2-negative and HER2-low breast cancer.

Dr Amengual on Tazemetostat, Lenalidomide, and Rituximab in Relapsed/Refractory FL

August 23rd 2023

Jennifer Effie Amengual, MD, discusses considerations for community oncologists looking to refer patients with relapsed/refractory follicular lymphoma (FL) to the ongoing second-line, phase 3 SYMPHONY-1 trial (NCT04224493).

Dr Hansford on the FIREFLY-1 Trial of Tovorafenib in Pediatric Low-Grade Glioma

August 23rd 2023

Jordan Hansford, MD, discusses the phase 2 FIREFLY-1 trial, which is investigating the pan-RAF inhibitor tovorafenib (DAY101) in children and young adults with low-grade glioma.

Dr Cannon on the Investigation of the Th17 Dendritic Cell Vaccine in Ovarian Cancer

August 23rd 2023

Martin Cannon, PhD, discusses the phase 1 investigation of the Th17 dendritic cell vaccine in ovarian cancer, and how it could potentially improve suboptimal responses when treated with immunotherapy alone in this population.

Dr Mead on the Shifting Role of Ibrutinib in the Treatment of MCL

August 23rd 2023

Monica D. Mead, MD, discusses the impact of key data on the role of ibrutinib in the treatment of mantle cell lymphoma.

Dr Sonpavde on the Importance of Utilizing Precision Medicine in Bladder Cancer

August 22nd 2023

Guru P. Sonpavde, MD, discusses the importance of utilizing precision medicine in bladder cancer, and highlights the rationales and designs of the ongoing phase 3 EV-302 and AMBASSADOR trials.

Dr Tarantino on the Use of ADCs in HR+ Breast Cancer

August 22nd 2023

Paolo Tarantino, MD, discusses the use of antibody drug conjugates in patients with hormone receptor-positive breast cancer.

Dr Alumkal on Triplet Therapy in Prostate Cancer

August 22nd 2023

Joshi Alumkal, MD, discusses the use of triplet therapy in prostate cancer.

Dr Birrer on the Potential Utility of ADCs in Platinum-Resistant Ovarian Cancer

August 22nd 2023

Michael J. Birrer, MD, PhD, discusses how the expansion of antibody-drug conjugates can address the need for more effective regimens in platinum-resistant ovarian cancer.

Dr Hitchins on Investigating Constitutional MLH1 Methylation in CRC and Endometrial Cancers

August 22nd 2023

Megan Hitchins, PhD, discusses the rationale for conducting an analysis on the prevalence of high-risk constitutional MLH1 methylation in patients with early-onset colorectal cancer and endometrial cancer.

Dr Moore on the Phase 1/2 Study Investigating Ubamatamab in Ovarian Cancer

August 21st 2023

Kathleen N. Moore, MD, MS, discusses the eligibility criteria for the ongoing, first-in-human, phase 1/2 study of ubamatamab, a MUC16- and CD3-targeted bispecific antibody, alone or in combination with cemiplimab in patients with recurrent ovarian cancer.

Dr McDermott on the Eligibility Criteria of the LITESPARK-024 Trial in RCC

August 21st 2023

David F. McDermott, MD, discusses the ongoing, randomized, phase 1/2 LITESPARK-024 trial in patients with advanced renal cell carcinoma, highlighting the eligibility criteria for this clinical trial.

Dr Mascarenhas on the Goals of the Phase 1/2 KRT-232-109 Study in Myelofibrosis

August 21st 2023

John Mascarenhas, MD, discusses the goals of the phase 1/2 KRT-232-109 study evaluating the addition of the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in patients with primary or secondary myelofibrosis and highlights the eligibility criteria of this trial.

Dr Fakih on the BASECAMP-1 Study in HLA-A*0201-Positive Solid Tumors

August 21st 2023

Marwan G. Fakih, MD, discusses the main objective and design of the observational BASECAMP-1 study and how it functions alongside the phase 1/2 EVEREST-1 study in patients with solid tumors.

Dr Schinke on the Safety Profile of Talquetamab in Relapsed/Refractory Myeloma

August 21st 2023

Carolina D. Schinke, MD, discusses the safety profile of talquetamab-tgvs in the phase 1/2 MonumenTAL-1 trial of patients with relapsed/refractory multiple myeloma.

Dr Byndloss on the Relationship Between the Gut Microbiome and GI Cancers

August 18th 2023

Mariana X. Byndloss, DVM, PhD, discusses how the gut microbiome influences human health, highlighting the relationship between the gut microbiome and a person’s risk for developing gastrointestinal cancers, as well as characteristics of a healthy gut microbiome.

Dr Luke on the Background of the KEYNOTE-716 Trial in High-Risk Melanoma

August 18th 2023

Jason Luke, MD, FACP, discusses the background of the phase 3 KEYNOTE-716 trial of pembrolizumab vs placebo as adjuvant therapy in patients with stage IIB or IIC melanoma, highlighting previous data from the trial that led to the 36-month follow-up report.

Dr Ravi on the Use of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

August 18th 2023

Praful K. Ravi, MB, BChir, MRCP, discusses the use of prostate-specific membrane antigen-targeted therapies in metastatic castration-resistant prostate cancer, highlighting the use of the targeted radioligand lutetium Lu 177 vipivotide tetraxetan.